Kalm Therapeutics

Executive Summary

Kalm Therapeutics is a preclinical-stage biotech company based in Cambridge, MA, founded in 2018. The company is developing the first prescription patch treatment for chronic inflammatory skin diseases, specifically atopic dermatitis (eczema) and psoriasis. Its mission is to create natural medicines with clinical validation for chronic diseases. The patch technology aims to provide a non-invasive, convenient alternative to topical creams and systemic therapies, potentially improving patient compliance and outcomes. As a private, early-stage company, Kalm has not disclosed total funding or valuation, but its innovative approach targets large dermatology markets with significant unmet needs. The company's progress remains under the radar, and its success hinges on advancing preclinical studies and securing regulatory clearance for human trials.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Data Readout for Eczema Patch40% success
• Q2 2027IND Filing with FDA30% success